Evidence map›Paper›PMID 27566060›Full record

ArticleBioengineered2016

Expression and purification of recombinant TAT-BoNT/A

Parvaneh Saffarian, Shahin Najar Peerayeh, Jafar Amani, Firooz Ebrahimi, Hamid Sedighianrad, Raheleh Halabian, Abbas Ali Imani Fooladi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Novel Native and Engineered Botulinum Neurotoxins.Handbook of experimental pharmacology · 2021
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Parvaneh Saffariana Department of Microbiology , Tehran Medical Sciences Branch, Islamic Azad University , Tehran , Iran.
Shahin Najar Peerayehb Department of Bacteriology , Faculty of Medical Sciences, Tarbiat Modares University , Tehran , Iran.
Jafar Amanid Department of Biology , Faculty of Basic Sciences, Imam Hussein University , Tehran , Iran.
Firooz Ebrahimic Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences , Tehran , Iran.
Hamid Sedighianradc Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences , Tehran , Iran.
Raheleh Halabianc Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences , Tehran , Iran.
Abbas Ali Imani Fooladic Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences , Tehran , Iran.
Baqiyatallah University of Medical Sciences · IRImam Hossein University · IRIslamic Azad University Medical Branch of Tehran · IRTarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum toxin type A can temporarily inhibit muscle contraction. Currently, physicians administer this toxin as a bio-drug in treatment of some muscle contraction disorders. TAT-BoNT/A

Indexed as

Botulinum Toxins, Type ACloning, MolecularEscherichia coliIndustrial MicrobiologyRecombinant ProteinsBotulinum Toxins, Type ARecombinant Proteinscell-penetrating peptideinclusion bodylight chain of botulinum toxin type Aprotein expressionTAT-BoNT/A(1–448)

Identifiers

PMID27566060
PMCPMC5241812
OpenAlexW2508397440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.